Insider Selling: Sana Biotechnology, Inc. (NASDAQ:SANA) Insider Sells 290,912 Shares of Stock

Sana Biotechnology, Inc. (NASDAQ:SANA) insider Fmr Llc sold 290,912 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now directly owns 4,541,511 shares in the company, valued at $29,474,406.39. The trade was a 6.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Sana Biotechnology Price Performance

SANA traded down $0.64 on Friday, reaching $3.66. The company’s stock had a trading volume of 28,914,018 shares, compared to its average volume of 37,108,848. Sana Biotechnology, Inc. has a 1 year low of $1.52 and a 1 year high of $12.00. The business’s 50 day moving average is $2.40 and its 200 day moving average is $4.07. The stock has a market cap of $817.16 million, a price-to-earnings ratio of -2.61 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. As a group, research analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SANA. HC Wainwright increased their price target on Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. Finally, TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

Hedge Funds Weigh In On Sana Biotechnology

Hedge funds have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new stake in Sana Biotechnology during the third quarter worth about $29,000. Stifel Financial Corp acquired a new stake in Sana Biotechnology in the third quarter worth $43,000. EP Wealth Advisors LLC bought a new stake in Sana Biotechnology in the third quarter valued at $45,000. Blue Trust Inc. boosted its holdings in shares of Sana Biotechnology by 1,246.6% during the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after acquiring an additional 12,154 shares during the period. Finally, Algert Global LLC bought a new position in shares of Sana Biotechnology during the second quarter worth about $73,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.